抑制纺锤体阑尾冷却线圈蛋白 1 (SPDL1) 的表达可以减缓疾病进展，并与食管癌患者的不良预后相关。然而，SPDL1在食管鳞状细胞癌（ESCC）中的具体作用和分子机制尚未被探索。当前的研究旨在利用癌症基因组图谱 (TCGA) 和基因表达综合数据库的数据通过转录组分析来研究 ESCC 中 SPDL1 的表达水平。此外，利用机器学习和生物信息学确定了 SPDL1 所涉及的生物学作用、分子机制和蛋白质网络。采用细胞计数试剂盒8法、EdU染色法和transwell法研究抑制SPDL1表达对ESCC细胞增殖、迁移和侵袭的影响。最后，通过分析TCGA数据库的数据来评估SPDL1表达与癌症免疫浸润细胞之间的相关性。结果显示SPDL1在ESCC组织中过度表达。 ESCC患者SPDL1的表达与年龄相关。 SPDL1共表达基因包括那些参与细胞分裂、细胞周期、DNA修复和复制、细胞衰老和其他过程的基因。 SPDL1相关长非编码RNA的高危评分与ESCC患者的总生存期和癌症进展显着相关（P < 0.05）。抑制SPDL1表达可有效抑制ESCC TE-1细胞的增殖、迁移和侵袭（P < 0.05）。 SPDL1的过表达与Th2和辅助性T细胞的水平呈正相关，与浆细胞样树突状细胞和肥大细胞的水平呈负相关。总之，SPDL1 在 ESCC 中过度表达，并与免疫细胞相关。此外，抑制SPDL1表达可以有效减缓癌细胞的生长和迁移。 SPDL1 是治疗 ESCC 患者的一种有前途的生物标志物。版权所有：© 2024 Liu 等人。这是一篇根据知识共享署名许可条款分发的开放获取文章，允许在任何媒体上不受限制地使用、分发和复制，前提是注明原始作者和来源。

Inhibiting the expression of spindle appendix cooled coil protein 1 (SPDL1) can slow down disease progression and is related to poor prognosis in patients with esophageal cancer. However, the specific roles and molecular mechanisms of SPDL1 in esophageal squamous cell carcinoma (ESCC) have not been explored yet. The current study aimed to investigate the expression levels of SPDL1 in ESCC via transcriptome analysis using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases. Moreover, the biological roles, molecular mechanisms, and protein networks involved in SPDL1 were identified using machine learning and bioinformatics. The cell counting kit-8 assay, EdU staining, and transwell assay were used to investigate the effects of inhibiting SPDL1 expression on ESCC cell proliferation, migration, and invasion. Finally, the correlation between the SPDL1 expression and cancer immune infiltrating cells was evaluated by analyzing data from the TCGA database. Results showed that SPDL1 was overexpressed in the ESCC tissues. The SPDL1 expression was related to age in patients with ESCC. The SPDL1 co-expressed genes included those involved in cell division, cell cycle, DNA repair and replication, cell aging, and other processes. The high-risk scores of SPDL1-related long non-coding RNAs were significantly correlated with overall survival and cancer progression in patients with ESCC (P < 0.05). Inhibiting the SPDL1 expression was effective in suppressing the proliferation, migration, and invasion of ESCC TE-1 cells (P < 0.05). The overexpression of SPDL1 was positively correlated with the levels of Th2 and T-helper cells, and was negatively correlated with the levels of plasmacytoid dendritic cells and mast cells. In conclusion, SPDL1 was overexpressed in ESCC and was associated with immune cells. Further, inhibiting the SPDL1 expression could effectively slow down cancer cell growth and migration. SPDL1 is a promising biomarker for treating patients with ESCC.Copyright: © 2024 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.